TABLE OF CONTENTS
Volume 86, Issue 1 (July 2009)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use |
Corrigendum
In This Issue
In This Issue
In This Issue
Clin Pharmacol Ther 86: 1; doi:10.1038/clpt.2009.96
See also: Macroscopy by WoodcockSee also: Point/Counterpoint by AltmanSee also: State of the Art by Lathia et al. See also: Article by Vormfelde et al. See also: Article by Barker et al.Editorial
Editorial
Biomarkers: Principles, Policies, and Practice
JA Wagner
Clin Pharmacol Ther 86: 3-7; doi:10.1038/clpt.2009.77
News & Views
Highlights
Highlights
Clin Pharmacol Ther 86: 8-9; doi:10.1038/clpt.2009.91
ASCPT News
ASCPT News
Clin Pharmacol Ther 86: 10-11; doi:10.1038/clpt.2009.84
Macroscopy
Chutes and Ladders on the Critical Path:Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug Development
J Woodcock
Clin Pharmacol Ther 86: 12-14; doi:10.1038/clpt.2009.33
Perspectives
Point/Counterpoint
Direct-to-Consumer Genetic Testing: Failure Is Not an Option
RB Altman
Clin Pharmacol Ther 86: 15-17; doi:10.1038/clpt.2009.63
See also: Point/Counterpoint by Schickedanz & HerdmanDirect-to-Consumer Genetic Testing: The Need to Get Retail Genomics Right
AD Schickedanz and RC Herdman
Clin Pharmacol Ther 86: 17-20; doi:10.1038/clpt.2009.56
See also: Point/Counterpoint by AltmanOpinion
Personalized Medicine: A Perk of Privilege?
JJ Griggs
Clin Pharmacol Ther 86: 21-23; doi:10.1038/clpt.2009.75
Educating for Personalized Medicine: A Perspective From Oncology
DR Parkinson and J Ziegler
Clin Pharmacol Ther 86: 23-25; doi:10.1038/clpt.2009.76
Commentaries
Biomarkers in Clinical Drug Development
JVS Gobburu
Clin Pharmacol Ther 86: 26-27; doi:10.1038/clpt.2009.57
See also: State of the Art by Lathia et al.Addressing the Challenges of the Clinical Application of Pharmacogenetic Testing
ON Ikediobi, J Shin, RL Nussbaum and KA Phillips and the UCSF Center for Translational and Policy Research on Personalized Medicine (group authors: JM Walsh, U Ladabaum and D Marshall)
Clin Pharmacol Ther 86: 28-31; doi:10.1038/clpt.2009.30
State of the Art
State of the Art
The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
CD Lathia, D Amakye, W Dai, C Girman, S Madani, J Mayne, P MacCarthy, P Pertel, L Seman, A Stoch, P Tarantino, C Webster, S Williams and JA Wagner
Clin Pharmacol Ther 86: 32-43; advance online publication, May 27, 2009; doi:10.1038/clpt.2009.69
See also: Commentary by GobburuResearch
Reports
Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
PW Wirtz, JJ Verschuuren, JG van Dijk, ML de Kam, RC Schoemaker, JGC van Hasselt, MJ Titulaer, UR Tjaden, J den Hartigh and JMA van Gerven
Clin Pharmacol Ther 86: 44-48; advance online publication, April 8, 2009; doi:10.1038/clpt.2009.35
Bronchodilatory Effect of the PPAR-
Agonist Rosiglitazone in Smokers With Asthma
M Spears, I Donnelly, L Jolly, M Brannigan, K Ito, C McSharry, J Lafferty, R Chaudhuri, G Braganza, P Bareille, L Sweeney, IM Adcock, PJ Barnes, S Wood and NC Thomson
Clin Pharmacol Ther 86: 49-53; advance online publication, April 8, 2009; doi:10.1038/clpt.2009.41
Articles
Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
SV Vormfelde, J Brockmöller, S Bauer, P Herchenhein, J Kuon, I Meineke, I Roots and J Kirchheiner
Clin Pharmacol Ther 86: 54-61; advance online publication, April 15, 2009; doi:10.1038/clpt.2009.40
Comparison of Dose-Finding Designs for Narrow-Therapeutic-Index Drugs: Concentration-Controlled vs. Dose-Controlled Trials
R Lledó-García, S Hennig and MO Karlsson
Clin Pharmacol Ther 86: 62-69; advance online publication, April 1, 2009; doi:10.1038/clpt.2009.23
See also: Article by Lledó-García et al.The Influence of Underlying Assumptions on Evaluating the Relative Merits of Concentration-Controlled and Dose-Controlled Trials
R Lledó-García, S Hennig and MO Karlsson
Clin Pharmacol Ther 86: 70-76; advance online publication, March 11, 2009; doi:10.1038/clpt.2009.24
See also: Article by Lledó-García et al.Mechanistic Modeling of a Magnetic Marker Monitoring Study Linking Gastrointestinal Tablet Transit, In Vivo Drug Release, and Pharmacokinetics
M Bergstrand, E Söderlind, W Weitschies and MO Karlsson
Clin Pharmacol Ther 86: 77-83; advance online publication, April 22, 2009; doi:10.1038/clpt.2009.43
Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia
LE Friberg, R de Greef, T Kerbusch and MO Karlsson
Clin Pharmacol Ther 86: 84-91; advance online publication, April 22, 2009; doi:10.1038/clpt.2009.44
Discovery & Development
Discovery
Biomarker Discovery: Identification of a Growth Factor Gene Signature
A Loboda, M Nebozhyn, C Cheng, R Vessey, P Huang, H Dai and JW Watters
Clin Pharmacol Ther 86: 92-96; advance online publication, April 22, 2009; doi:10.1038/clpt.2009.48
Translational Medicine
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
AD Barker, CC Sigman, GJ Kelloff, NM Hylton, DA Berry and LJ Esserman
Clin Pharmacol Ther 86: 97-100; advance online publication, May 13, 2009; doi:10.1038/clpt.2009.68
Development
QT as a Safety Biomarker in Drug Development
DJ Whellan, CL Green, JP Piccini and MW Krucoff
Clin Pharmacol Ther 86: 101-104; advance online publication, May 27, 2009; doi:10.1038/clpt.2009.70
The Clinical Utility Index as a Practical Multiattribute Approach to Drug Development Decisions
B Poland, FL Hodge, A Khan, RT Clemen, JA Wagner, K Dykstra and R Krishna
Clin Pharmacol Ther 86: 105-108; advance online publication, May 20, 2009; doi:10.1038/clpt.2009.71
Regulation & Use
Practice
Clinically Available Pharmacogenomics Tests
DA Flockhart, T Skaar, DS Berlin, TE Klein and AT Nguyen
Clin Pharmacol Ther 86: 109-113; advance online publication, April 15, 2009; doi:10.1038/clpt.2009.39
